ACT-09 RETROSPECTIVE INVESTIGATION ABOUT STATUS AND RESULT OF ADMINISTRATION OF BEVACIZUMAB FOR MALIGNANT GLIOMAS IN THE REAL WORLD

摘要

6 years have passed after approval of Bevacizumab for malignant gliomas in Japan, we analyzed the application and the results in our institution. Subjects were 56 patients who were histologically diagnosed as malignant gliomas. Bevacizumab was used in 41 patients among them. In 14 patients, Bevacizumab was introduced after initial therapy. The resection rates were below partial resection in 11 of the 14 patients. In 12 patients, administrations were finished and the average use was 7.6 times. The reason was PD in 6, and side effect in 4. Eight patients died, the average OS of those who died was 9.9 months, the average PFS after Bevacizumab was 5.4 months, and the average time from discontinuation to death was 2.1 months. In 27 patients used at the time of recurrence, the initial excision rate tended to be higher than in the former cases. In 22 patients the administrations were finished and the average use was 11.1 times. The reason was PD in 17, and side effect in 4. Twenty patients have died, the average OS of those who died was 22.3 months, the average PFS after Bevacizumab was 7.1 months, and the average time from discontinuation to death was 2.6 months. In 12 of 15 unused patients subtotal or total resections were achieved. From results, when it is difficult to control by surgery or TMZ, Bevacizumab is used in most patients, and considering the nature of tumor, it can be said that all patients will be considered for use sometime. However, PFS after introduction is not good and the prognosis after discontinuation is poor. It is necessary to conduct initial treatment that can delay introduction, to provide care that does not lead to discontinuation due to side effects, and to examine what treatment is possible at the time of exacerbation.